CTI Molecular Imaging purchases fusion software company

CTI Molecular Imaging Inc. in August acquired all the capital stock of Mirada Solutions Ltd., a developer of fusion software applications for medical imaging workstations, for approximately $22 million.

 Miranda shareholders also may receive additional compensation based on its future financial results.

 The positron emission tomography (PET) developer and manufacturer plans to incorporate Mirada's image analysis and fusion software into all its PET scanner workstations to enhance analytical and diagnostic features. Mirada's software is designed to detect, diagnose and manage disease through image analysis tools.

 The acquisition also prompts CTI to take a one-time, non-cash pretax charge of approximately $1.3 million to write off Miranda's in-process research-and-development expenses.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.